Athira Pharma, Inc. (ATHA) Dividend History

Company News

• Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

  Athira Pharma announced positive results from a Phase 1 clinical trial of its drug candidate ATH-1105 in healthy volunteers, supporting continued development for the potential treatment of amyotrophic lateral sclerosis (ALS). The company plans to initiate a clinical trial in ALS patients in late 2025.

  GlobeNewswire Inc.
• Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up - Zacks Investment Research

  Athira Pharma has dosed the last patient in the phase II/III LIFT-AD study evaluating its pipeline candidate, fosgonimeton, for the treatment of mild-to-moderate Alzheimer's disease. The study is designed to assess the treatment effects of fosgonimeton across multiple aspects of the disease.

  Zacks Investment Research

  Featured Companies: ACRV ADPT RAPT
• Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients

  Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients

  GlobeNewswire Inc.
• Athira Pharma to Participate in Upcoming June Conferences

  Management to Highlight Robust Pipeline in Neurodegenerative Diseases with Key Phase 2/3 LIFT-AD Topline Data in Alzheimer’s Disease on Track for Second Half of 2024 Management to Highlight Robust Pipeline in Neurodegenerative Diseases with Key Phase 2/3 LIFT-AD Topline Data in Alzheimer’s Disease on Track for Second Half of 2024

  GlobeNewswire Inc.
• Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

  BOTHELL, Wash., May 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that the U.S. District Court for the Western District of Washington issued an order providing for preliminary approval of a proposed settlement of the claims asserted nominally on behalf of Athira against the individual defendants named in the previously disclosed stockholder derivative actions entitled Bushansky v. Kawas et al., No. 2:22-cv-497 and Houlihan v. Kawas et al., No. 2:22-cv-620, pending before the court. The proposed settlement calls for Athira to adopt certain corporate governance reforms and pay lead plaintiffs’ attorney’s fees, litigation expenses, and lead plaintiff service awards.

  GlobeNewswire Inc.